Novartis Sells Parts of Sandoz U.S. to India's Aurobindo for $900 Million

By REUTERS
NYT
Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million (696 million pounds), as the Swiss drugmaker looks to focus on higher growth areas.
Published date: September 6, 2018 at 07:04AM
Reuters
New York Times article